Trials / Conditions / Retinal Dystrophies

Retinal Dystrophies

21 registered clinical trials studyying Retinal Dystrophies — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherit NCT07502664	Ray Therapeutics, Inc.	—
Enrolling By Invitation	Real-time Acoustic Biofeedback for Enhancing Fixation Stability: A Proof-of-concept Study to Improve Ophthalmi NCT07529041	University Medical Center Goettingen	N/A
Recruiting	Natural History Study of Inherited Retinal Diseases NCT07085533	Zhongmou Therapeutics	—
Recruiting	A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreall NCT06852963	PYC Therapeutics	Phase 1 / Phase 2
Recruiting	The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration NCT06319872	University of Rochester	Phase 1
Completed	MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby) NCT06455826	PYC Therapeutics	Phase 1
Recruiting	Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retin NCT06375239	Ray Therapeutics, Inc.	—
Recruiting	SS-HH-OCT as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs) NCT06177977	Duke University	N/A
Active Not Recruiting	Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study NCT06162585	Nanoscope Therapeutics Inc.	—
Active Not Recruiting	Natural History of PRPF31 Mutation-Associated Retinal Dystrophy NCT05573984	PYC Therapeutics	—
Completed	Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] NCT04945772	Nanoscope Therapeutics Inc.	Phase 2
Recruiting	EyeConic: Qualification for Cone-Optogenetics NCT05294978	Institute of Molecular and Clinical Ophthalmology Basel	—
Unknown	An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerabil NCT04855045	ProQR Therapeutics	Phase 2 / Phase 3
Active Not Recruiting	A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigme NCT04123626	ProQR Therapeutics	Phase 1 / Phase 2
Completed	Dual Wavelength OCT NCT03843840	Moorfields Eye Hospital NHS Foundation Trust	—
Completed	Performance of Long-wavelength Autofluorescence Imaging NCT03592017	Oxford University Hospitals NHS Trust	N/A
Completed	Optical Head-Mounted Display Technology for Low Vision Rehabilitation NCT02983305	University of Michigan	N/A
Completed	Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy NCT03763227	Sultan Qaboos University	Phase 2
Completed	iPS Cells of Patients for Models of Retinal Dystrophies NCT03853252	University Hospital, Montpellier	N/A
Recruiting	Evaluation of Objective Perimetry Using Chromatic Multifocal Pupillometer NCT02014389	Sheba Medical Center	—
Completed	Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases NCT01546181	Institut National de la Santé Et de la Recherche Médicale, France	—